Why the study?
Do new anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) improve the prevention and treatment of VTE in medical patients compared to previous strategies?
Do new anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) improve the prevention and treatment of VTE in medical patients compared to previous strategies?
Factor Xa inhibitors and direct thrombin inhibitors represent important new options for VTE prevention and treatment in medical patients, requiring a tailored, multidisciplinary approach.
Answers are grounded in this paper and cite their sources.
May support tailored multidisciplinary VTE prevention with factor Xa and thrombin inhibitors in medical patients; leaves open direct comparisons to legacy agents.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sumirtha Balaratnam (2009) conducted a review in Venous Thromboembolism (VTE). Factor Xa inhibitors and direct thrombin inhibitors was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: